Loading...
LUNG logo

Pulmonx CorporationNasdaqGS:LUNG Stock Report

Market Cap US$68.9m
Share Price
US$1.84
My Fair Value
US$6.75
72.7% undervalued intrinsic discount
1Y-74.8%
7D5.7%
Portfolio Value
​
View

Pulmonx Corporation

NasdaqGS:LUNG Stock Report

Market Cap: US$68.9m

Pulmonx (LUNG) Stock Overview

A commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. More details

LUNG fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 24.62% per year

Trading at good value compared to peers and industry

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($69M)

Volatile share price over the past 3 months compared to the US market

Significant insider selling over the past 3 months


LUNG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

LUNG logo
Pulmonx

Expanded Lung Screening And Aging Trends Will Unlock Opportunities

Key Takeaways Increased early detection, demographic trends, and strategic partnerships are expanding the patient base and supporting sustained demand and revenue growth for Pulmonx. Clinical validation, reimbursement stability, and geographic expansion are driving broader adoption, improving margins, and strengthening Pulmonx's earnings stability and growth prospects.
View narrative
US$6.75
FV
72.7% undervalued intrinsic discount
17.33%
Revenue growth p.a.
0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
30 days ago author updated this narrative
LUNG logo
Pulmonx

AI And CT Screening Will Expand COPD Care Worldwide

Key Takeaways Rapid expansion in lung screening and strong adoption in underpenetrated markets could drive much higher growth, margins, and market share than currently expected. Strategic ecosystem partnerships and a shift to value-based care position Pulmonx for sustained procedural growth, premium pricing, and durable competitive advantage.
View narrative
US$15.8
FV
88.4% undervalued intrinsic discount
16.56%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
23 days ago author updated this narrative
LUNG logo
Pulmonx

US Hospital Workflows Will Delay Progress Yet Recovery Will Follow

Key Takeaways Slow adoption, complex referral pathways, and hospital constraints in the U.S. could delay Pulmonx's revenue growth and near-term earnings improvement. Global cost pressures, long sales cycles, and challenges in clinical adoption may restrict scalability, margin expansion, and timely realization of new market opportunities.
View narrative
US$2.5
FV
26.4% undervalued intrinsic discount
12.07%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 1 month ago author updated this narrative
View Stock Community

Pulmonx Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pulmonx
Historical stock prices
Current Share PriceUS$1.84
52 Week HighUS$9.37
52 Week LowUS$1.47
Beta0.42
1 Month Change10.84%
3 Month Change-33.81%
1 Year Change-74.79%
3 Year Change-88.14%
5 Year Change-95.65%
Change since IPO-95.32%

Recent News & Updates

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward

Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward

Recent updates

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward

Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward

Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 26
Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%

Apr 11
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%
User avatar

LungTrax And Global Expansion Will Broaden Market Access

Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency.

Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 21
Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)

Feb 07
Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Pulmonx: Low Bar For Q2 Earnings

Jul 21

Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Apr 04
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Pulmonx: Revisiting Thesis Following Management Change

Mar 26

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Feb 23
Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Aug 01
Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Nov 08
Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Shareholder Returns

LUNGUS Medical EquipmentUS Market
7D5.7%1.8%1.2%
1Y-74.8%0.8%17.9%

Return vs Industry: LUNG underperformed the US Medical Equipment industry which returned 0.2% over the past year.

Return vs Market: LUNG underperformed the US Market which returned 18.7% over the past year.

Price Volatility

Is LUNG's price volatile compared to industry and market?
LUNG volatility
LUNG Average Weekly Movement16.4%
Medical Equipment Industry Average Movement8.3%
Market Average Movement6.4%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.0%

Stable Share Price: LUNG's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LUNG's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1995291Steve Williamsonpulmonx.com

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves.

Pulmonx Corporation Fundamentals Summary

How do Pulmonx's earnings and revenue compare to its market cap?
LUNG fundamental statistics
Market capUS$68.86m
Earnings (TTM)-US$56.94m
Revenue (TTM)US$90.55m
0.8x
P/S Ratio
-1.3x
P/E Ratio

Is LUNG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUNG income statement (TTM)
RevenueUS$90.55m
Cost of RevenueUS$24.39m
Gross ProfitUS$66.16m
Other ExpensesUS$123.10m
Earnings-US$56.94m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.40
Gross Margin73.07%
Net Profit Margin-62.88%
Debt/Equity Ratio53.7%

How did LUNG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 04:57
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pulmonx Corporation is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBofA Global Research
William PlovanicCanaccord Genuity
John YoungCanaccord Genuity